Increased Levels of Soluble Syndecan-1 in the Subretinal Fluid and the Vitreous of Eyes with Rhegmatogenous Retinal Detachment

REFERENCES

• Bernfield M, Gotte M, Park P W, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729–777
   PubMed Web of Science ®Google Scholar
• Grassme H, Gulbins E, Brenner B, et al. Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 1997; 91: 605–615
   PubMed Web of Science ®Google Scholar
• Rostand K S, Esko J D. Microbial adherence to and invasion through proteoglycans. Infect Immun 1997; 65: 1–8
   PubMed Web of Science ®Google Scholar
• Kim C W, Goldberger O A, Gallo R L, et al. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 1994; 5: 797–805
   PubMed Web of Science ®Google Scholar
• Kambham N, Kong C, Longacre T A, et al. Utility of syndecan-1 (CD138) expression in the diagnosis of undifferentiated malignant neoplasms: A tissue microarray study of 1,754 cases. Appl Immunohistochem Mol Morphol 2005; 13: 304–310
   PubMedGoogle Scholar
• Sanderson R D, Borset M. Syndecan-1 in B lymphoid malignancies. Ann Hematol 2002; 81: 125–135
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation. Blood 1998; 91: 2679–2688
   PubMed Web of Science ®Google Scholar
• Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 1998; 4: 691–697
   PubMed Web of Science ®Google Scholar
• Subramanian S V, Fitzgerald M L, Bernfield M. Regulated shedding of syndecan-1 and-4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 1997; 272: 14713–14720
   PubMed Web of Science ®Google Scholar
• Symeonidis C, Diza E, Papakonstantinou E, et al. Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol 2007; 245: 560–568
   PubMedGoogle Scholar
• Plantner J J, Jiang C, Smine A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Exp Eye Res 1998; 67: 637–645
   PubMed Web of Science ®Google Scholar
• The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 1983; 90: 121–125
   PubMed Web of Science ®Google Scholar
• La Heij E C, Blaauwgeers H G, de Vente J, et al. Decreased levels of cGMP in vitreous and subretinal fluid from eyes with retinal detachment. Br J Ophthalmol 2003; 87: 1409–1412
   PubMedGoogle Scholar
• Jerdan J A, Pepose J S, Michels R G, et al. Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 1989; 96: 801–810
   PubMed Web of Science ®Google Scholar
• Alexopoulou A N, Multhaupt H A, Couchman J R. Syndecans in wound healing, inflammation and vascular biology. Int J Biochem Cell Biol 2007; 39: 505–528
   PubMed Web of Science ®Google Scholar
• Watchorn T M, Waddell I, Ross J A. Proteolysis-inducing factor differentially influences transcriptional regulation in endothelial subtypes. Am J Physiol Endocrinol Metab 2002; 282: E763–E769
   PubMed Web of Science ®Google Scholar
• Gotte M, Joussen A M, Klein C, et al. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 2002; 43: 1135–1141
   PubMedGoogle Scholar
• Park P W, Pier G B, Preston M J, et al. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa. J Biol Chem 2000; 275: 3057–3064
   PubMed Web of Science ®Google Scholar
• Elenius V, Gotte M, Reizes O, et al. Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem 2004; 279: 41928–41935
   PubMedGoogle Scholar
• Wilkinson C P. Rhegmatogenous retinal detachment. Ophthalmology, D Yanoff, J S Duker. Mosby, St. Louis, MO 2004; 982–989
   Google Scholar
• Aylward G. Proliferative vitreoretinopathy. Ophthalmology, D Yanoff, J Duker. Mosby, St. Louis, MO 2004; 1002–1006
   Google Scholar
• Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 1998; 17: 77–98
   PubMed Web of Science ®Google Scholar
• Pastor J C, de la Rua E R, Martin F. Proliferative vitreoretinopathy: Risk factors and pathobiology. Prog Retin Eye Res 2002; 21: 127–144
   PubMed Web of Science ®Google Scholar
• Hiscott P S, Grierson I, McLeod D. Natural history of fibrocellular epiretinal membranes: A quantitative, autoradiographic, and immunohistochemical study. Br J Ophthalmol 1985; 69: 810–823
   PubMed Web of Science ®Google Scholar
• Baudouin C, Fredj-Reygrobellet D, Gordon W C, et al. Immunohistologic study of epiretinal membranes in proliferative vitreoretinopathy. Am J Ophthalmol 1990; 110: 593–598
   PubMed Web of Science ®Google Scholar
• Kirchhof B, Sorgente N. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Dev Ophthalmol 1989; 16: 1–53
   PubMedGoogle Scholar
• Dieudonne S C, La Heij E C, Diederen R, et al. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2004; 45: 4113–4118
   PubMed Web of Science ®Google Scholar
• Charteris D G, Hiscott P, Robey H L, et al. Inflammatory cells in proliferative vitreoretinopathy subretinal membranes. Ophthalmology 1993; 100: 43–46
   PubMed Web of Science ®Google Scholar
• Baudouin C, Brignole F, Bayle J, et al. Class II histocompatibility antigen expression by cellular components of vitreous and subretinal fluid in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1991; 32: 2065–2072
   PubMedGoogle Scholar
• Brinkman C J, Broekhuyse R M. Cell-mediated immunity after retinal detachment as determined by lymphocyte stimulation. Am J Ophthalmol 1978; 86: 260–265
   PubMed Web of Science ®Google Scholar
• Limb G A, Little B C, Meager A, et al. Cytokines in proliferative vitreoretinopathy. Eye 1991; 5: 686–693
   PubMedGoogle Scholar
• Limb G A, Alam A, Earley O, et al. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 1994; 13: 791–798
   PubMed Web of Science ®Google Scholar
• Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8: 365–393
   PubMedGoogle Scholar
• Baudouin C, Brignole F, Bayle J, et al. Class II histocompatibility antigen expression by cellular components of vitreous and subretinal fluid in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1991; 32: 2065–2072
   PubMedGoogle Scholar
• Day R M, Mitchell T J, Knight S C, et al. Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine 2003; 21: 224–233
   PubMed Web of Science ®Google Scholar
• Seidel C, Sundan A, Hjorth M, et al. Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood 2000; 95: 388–392
   PubMed Web of Science ®Google Scholar
• Priglinger S G, Alge C S, Kreutzer T C, et al. Keratinocyte transglutaminase in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2006; 47: 4990–4997
   PubMedGoogle Scholar